Sean Anderson

Year In Review: Top Biosimilars-Related Regulatory Developments Of 2022

Celltrion USA Announces Submission Of BLA For Subcutaneous Infliximab Biosimilar

BPCIA Aflibercept Litigation: Regeneron Files 12(c) Motion To Dismiss Mylan's Counterclaim For Inequitable Conduct

The UK's MHRA Updates Its Guidance On Licensing Of Biosimilars

Celltrion Files IND With FDA For Adalimumab Biosimilar

EMA CHMP Recommends Grant Of Marketing Authorization For Three Biosimilars

JSR Life Sciences Launches New "Similis Bio" Business Division To Accelerate Biosimilar Development

FDA Announces Biosimilar Funding Opportunity